[Changing clinicians' prescription patterns].
In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner.
Reuther
Lene Ørskov
LØ
Klinisk Farmakologisk Enhed, Bispebjerg Hospital, DK-2400 København NV. lenereuther@hotmail.com
Christensen
Hanne Rolighed
HR
Mikkelsen
Camilla
C
D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000191:economics; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000191:economics; D003718:Denmark; D016527:Drug Costs; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000191:economics; D000069285:Infliximab; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D013810:Therapeutic Equivalency
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept